Jerome Roncalli

Prof. Jerome Roncalli

University Hospital, Toulouse, Occitanie, France
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2020 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
AMAnthony Matta
Anthony Matta
FBFrederic Bouisset
Frederic Bouisset
TLThibault Lhermusier
Thibault Lhermusier
FCFran Campelo-Parada
Fran Campelo-Parada
MEMeyer Elbaz
Meyer Elbaz
Jerome RoncalliJerome Roncalli
Jerome Roncalli
Coronary artery spasm (CAS) defined by a severe reversible diffuse or focal vasoconstriction is the most common diagnosis among INOCA (ischemia with no obstructive coronary artery disease) patients irrespective to racial, genetic, and geographic variations. However, the prevalence of CAS tends to decrease in correlation with the increasing use of medicines such as calcium channel blockers, angiotensin converting enzyme inhibitor, and statins, the controlling management of atherosclerotic risk factors, and the decreased habitude to perform a functional reactivity test in highly active cardiac catheterization centers. A wide spectrum of clinical manifestations from silent disease to sudden cardiac death was attributed to this complex entity with unclear pathophysiology. Multiple mechanisms such as the autonomic nervous system, endothelial dysfunction, chronic inflammation, oxidative stress, and smooth muscle hypercontractility are involved. Regardless of the limited benefits proffered by the newly emerged cardiac imaging modalities, the provocative test remains the cornerstone diagnostic tool for CAS. It allows to reproduce CAS and to evaluate reactivity to nitrates. Different invasive and noninvasive therapeutic approaches are approved for the management of CAS. Long-acting nondihydropyridine calcium channel blockers are recommended for first line therapy. Invasive strategies such as PCI (percutaneous coronary intervention) and CABG (coronary artery bypass graft) have shown benefits in CAS with significant atherosclerotic lesions. Combination therapies are proposed for refractory cases.

1 April 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
DGD. Guijarro
D. Guijarro
MLM. Lebrin
M. Lebrin
OLO. Lairez
O. Lairez
PBP. Bourin
P. Bourin
NPN. Piriou
N. Piriou
Jerome RoncalliJerome Roncalli
Jerome Roncalli

26 September 2021 in World Journal of Cardiology
Verified
Journal Article
Open access
AMAnthony Georges Matta
Anthony Georges Matta
NYNabil Yaacoub
Nabil Yaacoub
VNVanessa Nader
Vanessa Nader
NMNicolas Moussallem
Nicolas Moussallem
DCDidier Carrie
Didier Carrie
Jerome RoncalliJerome Roncalli
Jerome Roncalli
Coronary artery aneurysm: A review

23 June 2021 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
IRIman Razeghian-Jahromi
Iman Razeghian-Jahromi
AMAnthony G. Matta
Anthony G. Matta
RCRonan Canitrot
Ronan Canitrot
MZMohammad Javad Zibaeenezhad
Mohammad Javad Zibaeenezhad
MRMahboobeh Razmkhah
Mahboobeh Razmkhah
Jerome RoncalliJerome Roncalli
Jerome Roncalli
While existing remedies failed to fully address the consequences of heart failure, stem cell therapy has been introduced as a promising approach. The present review is a comprehensive appraisal of the impacts of using mesenchymal stem cells (MSCs) in clinical trials mainly conducted on ischemic cardiomyopathy. The benefits of MSC therapy for dysfunctional myocardium are likely attributed to numerous secreted paracrine factors and immunomodulatory effects. The positive outcomes associated with MSC therapy are scar size reduction, reverse remodeling, and angiogenesis. Also, a decreasing in the level of chronic inflammatory markers of heart failure progression like TNF-α is observed. The intense inflammatory reaction in the injured myocardial micro-environment predicts a poor response of scar tissue to MSC therapy. Subsequently, the interval delay between myocardial injury and MSC therapy is not yet determined. The optimal requested dose of cells ranges between 100 to 150 million cells. Allogenic MSCs have different advantages compared to autogenic cells and intra-myocardial injection is the preferred delivery route. The safety and efficacy of MSCs-based therapy have been confirmed in numerous studies, however several undefined parameters like route of administration, optimal timing, source of stem cells, and necessary dose are limiting the routine use of MSCs therapeutic approach in clinical practice. Lastly, pre-conditioning of MSCs and using of exosomes mediated MSCs or genetically modified MSCs may improve the overall therapeutic effect. Future prospective studies establishing a constant procedure for MSCs transplantation are required in order to apply MSC therapy in our daily clinical practice and subsequently improving the overall prognosis of ischemic heart failure patients.

3 February 2021 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
RIRomain Itier
Romain Itier
MGMaeva Guillaume
Maeva Guillaume
JRJean-Etienne Ricci
Jean-Etienne Ricci
FRFrançois Roubille
François Roubille
NDNicolas Delarche
Nicolas Delarche
Jerome RoncalliJerome Roncalli
Jerome Roncalli
The prevalence of non-alcoholic fatty liver disease (NAFLD) in heart failure (HF) preserved left ventricular ejection fraction (HFpEF) patients could reach 50%. Therefore, NAFLD is considered an emerging risk factor. In 20% of NAFLD patients, the condition progresses to non-alcoholic steatohepatitis (NASH), the aggressive form of NAFLD characterized by the development of fibrosis in the liver, leading to cirrhosis. The purpose of this review is to provide an overview of the relationships between NAFLD and HFpEF and to discuss its impact in clinical setting. Based on international reports published during the past decade, there is growing evidence that NAFLD is associated with an increased incidence of cardiovascular diseases, including impaired cardiac structure and function, arterial hypertension, endothelial dysfunction, and early carotid atherosclerosis. NAFLD and HFpEF share common risk factors, co-morbidities, and cardiac outcomes, in favour of a pathophysiological continuum. Currently, NAFLD and NASH are principally managed with non-specific therapies targeting insulin resistance like sodium-glucose co-transporter-2 inhibitors and liraglutide, which can effectively treat hepatic and cardiac issues. Studies including HFpEF patients are ongoing. Several specific NAFLD-oriented therapies are currently being developed either alone or as combinations. NAFLD diagnosis is based on a chronic elevation of liver enzymes in a context of metabolic syndrome and insulin resistance, with fibrosis scores being available for clinical practice. In conclusion, identifying HF patients at risk of NAFLD is a critically important issue. As soon as NAFLD is confirmed and its severity determined, patients should be proposed a management focused on symptoms and co-morbidities.

12 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
AMAnthony Matta
Anthony Matta
VNVanessa Nader
Vanessa Nader
MLMarine Lebrin
Marine Lebrin
FGFabian GROSS
Fabian GROSS
Anne-Catherine PratsAnne-Catherine Prats
Anne-Catherine Prats
Jerome RoncalliJerome Roncalli
Jerome Roncalli
Transplantation of mesenchymal stem cells (MSCs) in the setting of cardiovascular disease, such as heart failure, cardiomyopathy and ischemic heart disease, has been associated with good clinical outcomes in several trials. A reduction in left ventricular remodeling, myocardial fibrosis and scar size, an improvement in endothelial dysfunction and prolonged cardiomyocytes survival were reported. The regenerative capacity, in addition to the pro-angiogenic, anti-apoptotic and anti-inflammatory effects represent the main target properties of these cells. Herein, we review the different preconditioning methods of MSCs (hypoxia, chemical and pharmacological agents) and the novel approaches (genetically modified MSCs, MSC-derived exosomes and engineered cardiac patches) suggested to optimize the efficacy of MSC therapy.